LEO Pharma, the privately held Danish skin disease specialist, is fulfilling a five-year strategic ambition by linking up with Canadian medtech firm KLOX Technologies. LEO and KLOX have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize the Canadian firm's BioPhotonic technology platform, which includes a CE-approved treatment for moderate to severe acne.
While commercial terms have not been disclosed, LEO CEO and president Gitte Aabo confirmed to Scrip that her company's investment...